erlotinib hydrochloride has been researched along with chloroquine in 8 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 16,405 | 763 | 4,029 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | chloroquine (IC50) |
|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
| Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
| Procathepsin L | Homo sapiens (human) | 5.47 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
| Beta-secretase 1 | Homo sapiens (human) | 7 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ling, YH; Perez-Soler, R; Piperdi, B; Schwartz, EL; Sironi, J; Zou, Y | 1 |
| Bekerman, E; Einav, S | 1 |
| Abraham, RT; Bray, K; Cochran, N; De Jesus, R; Eng, CH; Fantin, VR; Fitzgerald, SL; Frias, E; George, E; Hoffman, GR; Lemon, L; Liu, S; Lucas, J; McAllister, G; Murphy, LO; Nyfeler, B; Tkach, D; Toral-Barza, L; Ugwonali, S; Wang, Z | 1 |
| Bulat, T; Golić, I; Incerti, S; Keta, O; Korać, A; Petrović, I; Ristić-Fira, A | 1 |
| Dong, X; Du, T; Li, Z; Wang, Z; Wu, G; Zhang, R | 1 |
| Knudson, CM; Kowalski, CE; Love-Homan, L; Orcutt, KP; Parsons, AD; Simons, AL; Sobhakumari, A | 1 |
| Chen, H; Gao, Y; Li, Z; Lv, T; Xu, L; Zhang, Y | 1 |
| Chesney, J; Dougherty, SM; Imbert-Fernandez, Y; Lanceta, L; Lypova, N | 1 |
8 other study(ies) available for erlotinib hydrochloride and chloroquine
| Article | Year |
|---|---|
The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
Topics: Animals; Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Chloroquine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Infectious disease. Combating emerging viral threats.
Topics: Adenine; Adenosine; Antiviral Agents; Benzamides; Chloroquine; Communicable Diseases, Emerging; Cyclosporins; Cytosine; Dengue; Drug Approval; Drug Design; Erlotinib Hydrochloride; Hemorrhagic Fever, Ebola; Humans; Imatinib Mesylate; Indoles; Organophosphonates; Piperazines; Purine Nucleosides; Pyrimidines; Pyrroles; Pyrrolidines; Quinazolines; Sunitinib; Viruses | 2015 |
Macroautophagy is dispensable for growth of KRAS mutant tumors and chloroquine efficacy.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Chloroquine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Knockout Techniques; Humans; Indoles; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrroles; Radiation Tolerance; Sunitinib; Ubiquitin-Activating Enzymes | 2016 |
The impact of autophagy on cell death modalities in CRL-5876 lung adenocarcinoma cells after their exposure to γ-rays and/or erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Chloroquine; DNA Breaks, Double-Stranded; DNA Repair; Erlotinib Hydrochloride; Gamma Rays; Humans; Lung Neoplasms | 2016 |
Autophagy inhibition facilitates erlotinib cytotoxicity in lung cancer cells through modulation of endoplasmic reticulum stress.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; RNA, Small Interfering; Transcription Factor CHOP | 2016 |
2-Deoxy-d-glucose Suppresses the In Vivo Antitumor Efficacy of Erlotinib in Head and Neck Squamous Cell Carcinoma Cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carrier Proteins; Cell Line, Tumor; Chloroquine; Deoxyglucose; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Female; Glucose; Head and Neck Neoplasms; Humans; Membrane Proteins; Mice; Mice, Nude; Protein Kinase Inhibitors; Squamous Cell Carcinoma of Head and Neck; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Transcription Factor CHOP; Xenograft Model Antitumor Assays | 2016 |
Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
Topics: Animals; Aptamers, Nucleotide; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Nanoparticles; Neoplasm Proteins; RNA, Small Interfering; Survivin; Xenograft Model Antitumor Assays | 2018 |
PFKFB3 Inhibition Impairs Erlotinib-Induced Autophagy in NSCLCs.
Topics: Adenylate Kinase; Autophagosomes; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Chloroquine; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Green Fluorescent Proteins; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutant Proteins; Phosphofructokinase-2; Protein Kinase Inhibitors; Sequestosome-1 Protein | 2021 |